Moderator:

Emily Bisson, APRN, CPNP
Nurse Practitioner, Connecticut Children’s Medical Center

 

Speaker:

Stacy E. Croteau, MD, MMS
Director, Hemophilia/VWD Program Boston Children’s Hospital
Medical Director, Boston Hemophilia Ctr Assistant Professor of Pediatrics, Harvard Medical School

 

After completing this activity, the participant should be better able to:

  • Describe the mechanism of action of 3 novel treatment modalities.
  • Discuss the clinical implications of future therapies for the care of patients with hemophilia, von Willebrand disease and rare bleeding disorders.
  • Evaluate the current state of gene therapy trials in hemophilia.